PhRMA ad guidelines quickly draw fire as weak, meaningless

PhRMA's new DTC ad guidelines have been released and quickly panned by industry critics. The new guidelines -- pieced together after a growing chorus of complaints highlighted how drug advertising has spurred inappropriate use and higher costs -- amount to little more than suggestions on how a drug company should conduct itself when putting together a campaign. An initiative in Congress calling for a two-year ban on ads for new drugs was countered by an industry suggestion that an "appropriate" amount of time elapse between a drug's approval and a consumer ad campaign. PhRMA President Billy Tauzin has called the suggestion of mandatory restrictions on drug advertising a "human rights abuse."

A host of big drug companies, including Merck and AstraZeneca, immediately applauded the new, voluntary approach, often vowing to continue policies already in place.

- read this story from Brandweek for more

PLUS: Ad execs say it's too soon to say what, if any, effect the new guidelines will have on the drug industry's $4 billion annual ad buy. Story

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.